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Early diagnosis of oesophageal cancer
EL Bird-Lieberman1 and RC Fitzgerald*,1
1MRC Cancer Cell Unit, Hutchison-MRC Research Centre, Hills Road, Cambridge CB22 0XZ, UK
Squamous cell carcinoma and adenocarcinoma of the oesophagus are cancers that develop from distinct epithelial sub-types;
however, they are both related to chronic inflammation of differing aetiologies. Inflammation leads to somatically inherited genetic
mutations altering control of the cell cycle, DNA replication and apoptosis, which together result in autonomous and uncontrolled
proliferation. These cancers have often metastasised to lymph nodes and distant organs before symptomatic presentation and
therefore carry a poor prognosis. It is therefore vital to diagnose oesophageal cancer at an early stage, before the development of
symptoms, when treatment can dramatically improve prognosis. Understanding the pathogenesis of these cancers is vital to guide
early diagnostic strategies.
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Cancer of the oesophagus presents symptomatically late in the
course of the disease and, despite currently available therapies,
carries a poor prognosis. The annual incidence of oesophageal
cancer in the United Kingdom is 9.6 out of 100 000 population and
it has a very similar annual mortality of 8.7 out of 100 000
population because of the overall poor 5-year survival rate of
under 10% (CRUK, 2009). Squamous cell carcinoma (SCC) and
adenocarcinoma (AC) are the two main histological types of
oesophageal cancer that will be discussed, although rarities, such
as adenoid cystic, mucoepidermoid, adenosquamous, small cell
carcinoma, sarcoma, melanoma and lymphoma, can occur.
For the purpose of this review ‘early’ oesophageal cancer will be
defined as high-grade dysplasia, or tumour limited to the mucosa
(Tin situ) or submucosa (T1) and not extending into the muscular
wall of the oesophagus.
The stage (classified according to the T, N, M system) at which
oesophageal cancer is detected is the most important factor in
determining prognosis. The rate of lymph node metastasis in both
SCC and AC is related to the depth of invasion and neither tend to be
associated with lymph node metastasis when invasion is limited to the
muscularis mucosa (Endo and Kawano, 1997; Ancona et al, 2008). The
majority of oesophageal cancers that present with symptoms have
invaded to the muscularis propria (T3) and have already spread to
local lymph nodes (N1); this is the reason for the poor prognosis.
In stark contrast to oesophageal cancers that present with
symptoms, the 5-year survival for early disease is over 90% (Wang
et al, 2009). The survival benefit is because treatments are more
effective at this early stage. These statistics should, however, be
interpreted with an element of caution because of the phenomenon
of lead time bias. When screening or surveillance detects a pre-
symptomatic cancer, the survival from this cancer will appear
longer than if it was diagnosed after the appearance of symptoms
at a later date, even if early intervention provided no benefit.
Historically, radical oesophagectomy was necessary to treat
early oesophageal cancer. Endoscopic therapeutic techniques
have, however, advanced rapidly in the last decade and can now
be used as an alternative for the treatment of early cancer (Singh
and Sharma, 2009). Endoscopic therapy can take the form of a
dissection of the superficial layers of the oesophageal lumen
(endoscopic mucosal or sub-mucosal resection) or generalised
mucosal ablation (e.g., radiofrequency ablation, photodynamic
therapy or argon plasma coagulation). Surgical techniques have
also evolved and laparoscopically assisted oesophagectomies are
being undertaken for early disease.
EPIDEMIOLOGY
Squamous cell oesophageal cancer
Squamous cell carcinoma accounts for the bulk of oesophageal
cancer worldwide, particularly in the developing world, and has
great geographical as well as sociocultural variation in incidence.
Some of the highest SCC rates are in northern China and northern
Iran where the incidence is 1 out of 1000. In the United States, SCC
rates fell by 3.6% each year between 1998 and 2002; this decrease
occurred in most ethnic groups and in both sexes (Trivers et al,
2008). This decrease in incidence is thought to be because of a
reduction in smoking.
Oesophageal adenocarcinoma
Adenocarcinoma accounts for up to 50% of oesophageal cancers in
the West, particularly in the male Caucasian population (Parkin
et al, 2002), in contrast to the prevalence of SCC in the developing
countries. In Britain, age-standardised incidence rates of AC have
risen by just under 40% every 5 years (Lepage et al, 2008), and
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have recently been highlighted by the Chief Medical Officer as a
‘serious pathological concern’.
CLINICAL STAGES OF DISEASE
Symptomatic presentation
The expansible nature of the oesophagus means that early cancers
rarely present symptomatically because circumferential involve-
ment, or considerable penetration into the lumen, is required to
cause dysphagia, and invasion into adjacent structures is required
to trigger pain. The diagnosis of early oesophageal cancer should
therefore not be focused at this late stage of the pathway, but
rather at asymptomatic individuals.
The detection of oesophageal cancer before the development
of symptoms requires screening and/or surveillance. In the West,
the preponderance of AC means that research into screening and
surveillance of oesophageal cancer has been focused on AC rather
than SCC.
Surveillance is the repeated application of a test (such as,
endoscopy) that allows detection of disease at a stage when
intervention may improve outcome. This process is made more
cost effective by limiting it to those at particular risk, for example,
those with Barrett’s epithelium (BE) (þ /dysplasia) who are at
increased risk of AC (Gerson et al, 2004). We would expect to
increase detection of early cancers if screening is used in addition
to surveillance, although if this was dependent on endoscopy, the
cost effectiveness may in turn be decreased. Screening is the one-
time application of the same test to allow detection of early cancers
and those at risk within the general population.
Surveillance for adenocarcinoma
In the United Kingdom, the current evidence for the overall benefit
of oesophageal surveillance programmes for AC is limited and they
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Figure 1 The common and distinct known aetiology and pathogenesis of oesophageal adenocarcinoma (AC) and squamous cell carcinoma (SCC).
Adenocarcinoma and SCC develop the characteristics of cancer through somatic mutations, some of which are shown above. The areas in which AC and
SCC overlap are shown in green.
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are not universally recommended (http://www.bsg.org.uk,
2005). However, in the absence of useful alternatives, patients
with known BE are usually offered the choice of entry into a
surveillance programme, which consists of endoscopic inspection
and multiple biopsies (taken from macroscopically abnormal areas
and quadrantically every 2 cm from areas, which have no
macroscopic features of cancer) every 2– 3 years. The only
biomarker currently used to guide endoscopic or surgical
intervention is high-grade dysplasia found within these biopsies,
but patches of dysplasia may be missed despite extensive
biopsying and thus false reassurance may be provided. It is
estimated that overall 0.6% of people with Barrett’s oesophagus
will progress to AC each year (Yousef et al, 2008). As a result of
this concern, many patients at very low risk continue to undergo
endoscopic surveillance.
Screening for adenocarcinoma
Currently Barrett’s oesophagus and squamous dysplasia are
diagnosed by endoscopy and biopsy. The associated balance of
risk, benefit, cost and psychological burden has not justified the
implementation of a national screening programme (Gerson et al,
2004). Barrett’s oesophagus is therefore generally diagnosed as
part of a general investigation for reflux or dyspepsia, or
incidentally during endoscopy for an alternate indication. New,
less invasive and cheaper screening tools are being sought; and
most current gastroenterology infrastructures would not be able to
support the introduction of an endoscopic screening program.
Screening for squamous cell cancer
Cytological screening techniques have been developed for the early
detection of SCC and have been used particularly in the Linxian
region of China, where there are large numbers of people who are
asymptomatic, but at high risk of SCC. A deflated balloon, covered
with netting, is swallowed, inflated when in the stomach, and
retracted along the oesophagus. Attached cells are smeared onto
slides, stained with Papanicolaou’s stain and examined (Dawsey
et al, 1997). This cytological diagnosis has low sensitivity
(14– 36%) for the detection of cancers, which have already been
detected on biopsy (Dawsey et al, 1997) and endoscopic screening
is taking place in preference.
ENDOSCOPIC TECHNIQUES AVAILABLE FOR EARLY
DIAGNOSIS
Traditional white-light endoscopy can identify macroscopic
features of early cancer, such as nodules, ulcers or strictures.
Unfortunately, early cancers, particularly at the high-grade
dysplasia stage, often appear macroscopically normal. Given the
Western preponderance of AC, newer endoscopic imaging
techniques have been focused in this area and are reviewed below.
Many of the newer techniques are plagued by the need for expert
histological knowledge to interpret images; they thus depend on
operator experience and may not be applicable to the general
endoscopic setting. These techniques are also time consuming and
rely on consistent operator technique and interpretation.
Chromoendoscopy
Chromoendoscopy is the application of a chemical capable of
selective light absorption, which results in colouration of certain
organic compounds to enhance endoscopic visualisation. The
application of Lugol’s iodine has been shown to improve
visualisation of SCC and its pre-cancerous stage (Dawsey et al,
1998). Methylene blue has also been used to improve detection of
dysplasia in Barrett’s oesophagus, but subjectivity has meant
results are difficult to reproduce (Ormeci et al, 2008), and there
has been some concern over potential carcinogenicity of methylene
blue (NTP, 2008).
Trimodal imaging
A trimodal endoscope, which combines the ability to provide
high-resolution white-light endoscopy, autofluorescence and
narrow-band imaging, is now commercially available. Auto-
fluorescence is used in an attempt to avoid many of the problems
associated with administration of exogenous chromophores.
There is limited randomised evidence to show improvement of
detection of high-grade dysplasia over white light alone (Kara et al,
2005), and it is particularly troubled by false positives. Narrow-
band imaging aims to highlight the vasculature and mucosal
pit pattern by filtering out longer wavelengths of light. Some
studies have shown some improvement in the detection of
dysplasia compared with white-light endoscopy (Wolfsen et al,
2008). Areas of concern, which seem to be more purple in colour
on autofluorescence can then be examined with narrow-band
imaging, with the aim of decreasing the false-positive rate (Kara
et al, 2006). Some clinical trials comparing trimodal imaging
with white-light endoscopy and random quadrantic biopsies have
shown an increased detection of dysplasia and early oesophageal
cancer (Curvers et al, 2008); however, this is not universally the
case (Kara et al, 2006).
Confocal fluorescence microscopy
Confocal fluorescence microscopy attempts to highlight morpho-
logical changes in tissue, which occur in dysplasia, through
imaging of the autofluorescence properties of the mucosa.
Excitation with blue light leads to emission of longer wavelengths
of light from molecules, such as haemoglobin or collagen. The
administration of intravenous fluorophores (e.g., fluorescein)
can improve depth of visualisation compared with using auto-
fluorescence alone.
Confocal fluorescence microscopy aims to provide an image
consistent with the histology of the tissue being examined in an in
vivo setting, but so far falls short of this aim. It was found to
achieve a high-negative predictive value (99%) in vivo, but
sensitivity was poor (positive predictive value 44%) (Pohl et al,
2008).
Elastic scattering spectroscopy
The epithelial elastic scattering index depends on the composition
of sub-cellular components, such as the nucleus and mitochondria,
which alter during malignant transformation. An optical probe can
be inserted through the instrument channel of the endoscope to
give a measurement, which eliminates the problems of observer
variability. This technique has been shown to have a high
sensitivity (92%), but poor specificity (60%) (Lovat et al, 2006).
However, prospective validation is awaited and elastic scattering
spectroscopy does not circumvent the problem of sampling error,
as it does not allow sampling of the entire segment.
Optical coherence tomography
Optical coherence tomography measures the backscattering of
infrared light to produce a high-resolution image of the epithelium
in cross section (up to 3 mm in depth), in a similar way to
ultrasound imaging. In vitro and ex vivo feasibility studies have
been promising, but in vivo studies showing adequate sensitivity
and specificity for detection of dysplasia are lacking at present
(Testoni and Mangiavillano, 2008).
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MOLECULAR PATHOGENESIS OF OESOPHAGEAL
CANCER
Both AC and SCC are thought to develop through a series of somatic
mutations or epigenetic changes. These genetic changes allow six of
the clinical characteristics of cancer to occur: resistance to growth-
inhibitory signals; autonomous proliferation; avoidance of apopto-
sis; unlimited replication; angiogenesis; and invasion and metastasis
(Hanahan and Weinberg, 2000). Many of the mutations, which lead
to these characteristics, will confer a survival benefit on the mutated
cells, and lead to clonal expansion at the expense of other cells.
Figure 1 shows the changes that have been shown to occur in the
pathogenesis of AC and SCC; many of these changes have been
suggested to be suitable biomarkers for the development of cancer.
Chronic inflammation is thought to be the precipitating factor in
both SCC and AC. In SCC, the chronic inflammation is thought to
be precipitated by toxins, including cigarettes, alcohol and
aflatoxin B1 (from mouldy food). In AC, the inflammation is
thought to be triggered by acid and bile reflux into the oesophagus
as this is the strongest risk factor for the development of the
columnar metaplasia known as BE (Conio et al, 2002). Barrett’s
epithelium increases the chance of developing AC to 0.5% per
patient per year (Shaheen et al, 2000) and it is thought that on-
going reflux and other factors, such as dietary nitrates contribute
to progression to cancer.
Molecular techniques that can be used on oesophageal
tissue
An ideal technique to determine high risk of progression to cancer
would not only be sensitive and specific, but would also be quick,
non-invasive and would not require specialist interpretation.
Endoscopic biopsy surveillance does not meet this ideal on many
levels. It is invasive and expensive, biopsy taking is laborious and
samples only a small area of the heterogeneous epithelium and
there is inter-observer variation in the time-consuming patholo-
gical interpretation. However, multiple biopsies, which have been
fixed in formalin, do allow immunohistochemistry to be
performed. Immunohistochemistry can inform about the presence
of certain biomarkers, their specific location within the tissue and
provide some quantitative information; immunohistochemistry for
MCM-2 and cyclin-A have been used, for example, to predict risk
of progression to AC (Lao-Sirieix et al, 2007).
Cytological sampling allows a more rapid sampling of a larger
surface of superficial epithelium compared with biopsies, but the
sampling is less specific because of contamination with other cells
and has been attempted in both AC and SCC. Harvesting cells for
cytological analysis can be performed at endoscopy using a brush
inserted through the instrument channel; however, it would be
preferable to obtain specimens in a less invasive manner. The
mesh-covered balloon method for obtaining cytology has already
been discussed.
Cytology for detection of squamous cell cancer
Cytological samples obtained by this method have been evaluated
for the presence of methylation of eight genes, which have been
shown to be methylated in SCC using quantitative methylation-
specific PCR. The best sensitivity and specificity was obtained
when a combination of four of these genes was used (AHRR,
p16INK4a, MT1G and CLDN3). However, they were not good
enough markers to be of clinical use as the sensitivity and
specificity were only 50 and 68%, respectively (Adams et al, 2008).
Cytology for screening for Barrett’s oesophagus
The capsule sponge is another method that has been developed for
obtaining cytological specimens in a minimally invasive manner.
The sponge is contained within a gelatine capsule, which dissolves
when it comes into contact with gastric contents. The sponge is
thus liberated and can then be withdrawn on a thread through the
mouth; this can be performed in a primary care setting. It is being
used to investigate molecular markers, MCM-2 and TFF3, in
screening for BE, but could also be used in surveillance if
appropriate biomarkers were available.
Automation of cytological analysis
Ideally, analysis of cytological samples could be automated to
minimise the need for time-consuming, operator-dependent
cytological analysis. Flow cytometry, fluorescent in situ hybridisa-
tion (FISH) and PCR are techniques for which automated systems
have been developed for the prediction of progression to AC.
Flow cytometry can be used to determine the percentage of cells
with tetraploidy, which is associated with progression to cancer
(Chao et al, 2008). The combination of a 4N fraction 46% with
aneuploidy (an independent risk variable) improved the predictive
power of flow cytometry. Unfortunately, flow cytometry requires a
larger number of cells than is obtained with brushings and needs
to be performed on biopsies, which sample only a small area.
Fluorescent in situ hybridisation makes use of fluorescently labelled
DNA probes to detect chromosomal changes, such as aneuploidy,
loss of tumour suppressor genes (e.g., p53 or p16) or oncogene
amplification (e.g., Her-2). Despite the availability of automated FISH
systems, the price and need for specialist analysis prevent its routine
use in a surveillance setting; however, automated systems may
improve in the future. Amplification of c-myc, EGFR and the 20q12
loci have been proposed as prognostic markers for the development
of dysplasia/AC and can be detected using FISH on brush cytology
specimens (Rygiel et al, 2008). It should be remembered that FISH
will not detect point mutations or hypermethylation.
Quantitative methylation-specific PCR has been used to
determine methylation status and levels of the genes p16, HPP1
and RUNX3. The variations in methylation of these genes have
been used, in combination with clinical data, to estimate risk of
progression to early cancer in Barrett’s oesophagus (Sato et al,
2008). These markers have progressed to retrospective studies to
define the criteria for a positive screening test.
Serum biomarkers
Identification of biomarkers for oesophageal cancer in serum is
attractive because of the ease of obtaining samples for analysis and
would be an ideal method for screening or surveillance in a primary
care setting. Tumours release their proteins into the circulation
when cells die and through active secretion. They also cause
systemic changes in cytokines and growth factors, and alterations in
the immunological profile because of cancer antigenicity. Anti-
bodies to the altered cancer glycome, such as the antibody to
a-fetoprotein (AFP), are already used in the diagnosis of other
cancers. An individual serum biomarker for oesophageal cancer
with sufficient sensitivity has yet to be identified. As our
understanding of the changes that take place in the development
of oesophageal cancer improve, more biomarkers are likely to be
identified. Given the limited sensitivity and specificity of bio-
markers, which have thus far been identified, it is most likely that a
panel of serum biomarkers will prove optimal. Biomarker array
systems are being developed that could automatically detect the
multiple markers of interest. In a small study of one such array, Fas
ligand was shown to have a sensitivity of 83% and a specificity of
100% for oesophageal AC (Kilic et al, 2008).
Blood might also be screened for tiny amounts of tumour-
specific DNA, for example, using methylation-specific PCR to look
for hypermethylation of the p16 promoter in SCC (Hibi et al, 2001)
or reverse-transcription PCR to look for DNp63 expression in
peripheral blood in SCC (Koike et al, 2002). Reverse-transcription
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PCR has shown that expression of squamous cell carcinoma
antigen 2 (SCCA2) mRNA in peripheral blood correlates well with
expression in the cancer itself and with levels of SCCA2 in
peripheral blood detected by ELISA. However, although blood
levels of SCCA2 mRNA increased along the pathway to cancer, this
test was not sufficiently sensitive to be used alone as a biomarker
(Yang et al, 2008).
CONCLUSION
Oesophageal cancer presents late and carries a grave prognosis. It
is hoped that understanding its pathogenesis will reveal bio-
markers that can be used to diagnose these cancers early in order
to improve outcome. Pre-cancerous changes are often associated
with a heterogeneous field change. Single biomarkers identified
thus far lack sufficient sensitivity and specificity and it is likely that
multiple markers will need to be employed simultaneously. This
biomarker profile approach may assist us not only in the early
diagnosis of the condition, but also guide management.
It is possible that the new endoscopic techniques in develop-
ment will allow us to image changes at the molecular level and
allow detection of biomarkers associated with high risk of
progression to cancer. Such a diagnostic endoscopic technique
could be combined with immediate endoscopic therapy to
eradicate mucosal areas of concern and prevent cancer
development.
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